MyHealthChecked PLC Agreement with Boots for extended retail launch (7765Z)

TIDMMHC

RNS Number : 7765Z

MyHealthChecked PLC

18 May 2023

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

MyHealthChecked PLC

( " MyHealthChecked " or the "Company " )

Agreement with Boots for retail launch of extended product portfolio

MyHealthChecked tests to be available on www.boots.com and in store.

MyHealthChecked PLC (AIM: MHC), the consumer home-testing healthcare company, announces that it has entered into an agreement ("Agreement") via its subsidiary Concepta Diagnostics Limited with Boots UK Limited ("Boots"), the health and beauty retailer and pharmacy group, to launch its extended range of at-home self-testing products tests via boots.com and across Boots stores in Great Britain and Northern Ireland.

Under the agreement, a range of fourteen different test panels will launch during May 2023 comprising two blood and urine sample kits, seven blood prick sample kits and five DNA cheek swab kits. The tests and sample collection kits are available for applications such as thyroid function, food intolerances and sensitivities and vitamin profiles. The tests will be launched online and selected test kits will then be rolled out across approximately 120 Boots stores in Great Britain and Northern Ireland. All of the test kits are available for consumers to purchase directly from Boots stores or boots.com. The samples for these tests need to be posted and are tested at an accredited lab, after which, the blood and urine results are verified by a GP, who will provide advice on any actions the patient should take. The agreement is on a non-exclusive basis and has an initial term of 12 months from 17 May 2023.

In addition to the 14 tests under the agreement, a further six lateral flow tests will be launched online and in over 800 stores. These are done at home without needing to send a sample to the laboratory and the result is provided on the lateral flow device. This new product portfolio follows the successful launch of MyHealthChecked's COVID-19 PCR test kits via Boots online and in stores during 2021, and the distribution of FlowFlex(TM) lateral flow tests, which are also available online and in-store.

Penny McCormick, Chief Executive Officer of MyHealthChecked PLC, said: " We are delighted to be working with Boots with the launch of our extended portfolio of at-home tests online and in stores, whilst demonstrating execution of the next stage of our strategic plan. Our tests reflect a change in consumer needs as we see more customers take their health into their own hands. Following the launch of our extended product portfolio, our focus will turn towards ongoing customer guidance as we self-fund our investment in the evolution of our technology platform ."

For further information contact:

 
 MyHealthChecked PLC                                                www.myhealthchecked.com 
 Penny McCormick, Chief Executive                                           via Walbrook PR 
  Officer 
 
 SPARK Advisory Partners Limited                                   Tel: +44 (0)20 3368 3550 
  (NOMAD) 
 Neil Baldwin 
 
 Dowgate Capital Limited (Broker)                                  Tel: +44 (0)20 3903 7715 
 David Poutney / Nicholas Chambers 
 
 Walbrook PR Ltd (Media       Tel: +44 (0)20 7933 8780 or myhealthcheckedplc@walbrookpr.com 
  & IR) 
 Paul McManus / Alice Woodings                               Mob: +44 (0)7980 541 893 / +44 
                                                                            (0)7407 804 654

About MyHealthChecked PLC ( https://investors.myhealthchecked.com/ )

MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK healthcare company focused on a range of at-home healthcare and wellness tests.

MyHealthChecked is the umbrella brand of a range of at-home rapid tests, as well as DNA, RNA and blood sample collection kits which have been created to support customers on their journeys to wellness. The tests are lateral-flow self-tests, whilst the sample collection kits enable the collection of blood, urine, nasal or mouth swab samples that are analysed in partner laboratories for a range of biomarkers. The tests will also be made available online and will be viable for over-the-counter purchase.

The MyHealthChecked portfolio has been identified as part of a change in mindset as customers become more familiar with the concept of accessible healthcare in the growing at home testing kit market with a focus on accessibility at the right price, led by UK-based experts.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

AGRMZGMKKNVGFZM

(END) Dow Jones Newswires

May 18, 2023 02:00 ET (06:00 GMT)

Myhealthchecked (LSE:MHC)
Historical Stock Chart
From Nov 2024 to Dec 2024